Switch theme
Sign up to access all valuation multiples
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
2017
n/a
LTM Revenue $1.0M
Last FY EBITDA -$17.3M
$231M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Tvardi Therapeutics has a last 12-month revenue (LTM) of $1.0M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Tvardi Therapeutics achieved revenue of n/a and an EBITDA of -$17.3M.
Tvardi Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tvardi Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$17.3M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$39.1M | XXX | -$18.7M | XXX | XXX | XXX |
| EBIT Margin | -4069% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$31.3M | XXX | -$17.3M | XXX | XXX | XXX |
| Net Margin | -3260% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Tvardi Therapeutics's stock price is $26.
Tvardi Therapeutics has current market cap of $240M, and EV of $231M.
See Tvardi Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $231M | $240M | XXX | XXX | XXX | XXX | $-2.35 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Tvardi Therapeutics has market cap of $240M and EV of $231M.
Tvardi Therapeutics's trades at n/a EV/Revenue multiple, and -13.4x EV/EBITDA.
Equity research analysts estimate Tvardi Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tvardi Therapeutics has a P/E ratio of -7.7x.
See valuation multiples for Tvardi Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $240M | XXX | $240M | XXX | XXX | XXX |
| EV (current) | $231M | XXX | $231M | XXX | XXX | XXX |
| EV/Revenue | 241.0x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -13.4x | XXX | XXX | XXX |
| EV/EBIT | -5.9x | XXX | -12.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.7x | XXX | -13.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -11.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTvardi Therapeutics's last 12 month revenue growth is -84%
Tvardi Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Tvardi Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tvardi Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Tvardi Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -84% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Race Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Supriya Lifescience | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascentage Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| ST Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Alpha Cognition | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tvardi Therapeutics acquired XXX companies to date.
Last acquisition by Tvardi Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Tvardi Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Tvardi Therapeutics founded? | Tvardi Therapeutics was founded in 2017. |
| Where is Tvardi Therapeutics headquartered? | Tvardi Therapeutics is headquartered in United States of America. |
| Who is the CEO of Tvardi Therapeutics? | Tvardi Therapeutics's CEO is Dr. Imran Nizamudin Alibhai, PhD. |
| Is Tvardi Therapeutics publicy listed? | Yes, Tvardi Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Tvardi Therapeutics? | Tvardi Therapeutics trades under TVRD ticker. |
| When did Tvardi Therapeutics go public? | Tvardi Therapeutics went public in 2025. |
| Who are competitors of Tvardi Therapeutics? | Similar companies to Tvardi Therapeutics include e.g. Race Oncology, Supriya Lifescience, Ascentage Pharma Group, ST Pharm. |
| What is the current market cap of Tvardi Therapeutics? | Tvardi Therapeutics's current market cap is $240M |
| What is the current revenue of Tvardi Therapeutics? | Tvardi Therapeutics's last 12 months revenue is $1.0M. |
| What is the current revenue growth of Tvardi Therapeutics? | Tvardi Therapeutics revenue growth (NTM/LTM) is -84%. |
| What is the current EV/Revenue multiple of Tvardi Therapeutics? | Current revenue multiple of Tvardi Therapeutics is 241.0x. |
| Is Tvardi Therapeutics profitable? | Yes, Tvardi Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
